Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
Lopinavir/ritonavir monotherapy is currently a well known and widely used strategy, while
Lopinavir/ritonavir 800/200 mg once a day in a triple-therapy was approved a few years ago.
The purpose of this study is to evaluate efficacy and safety of Lopinavir/ritonavir 800/200
mg monotherapy once a day.